ALB and chronic kidney disease: Finerenone has been shown to reduce urinary albumin-to-creatinine ratio in patients with CKD in clinical trials, and decreased cardiovascular morbidity and mortality in patients with advanced CKD and T2DM in the FIGARO-DKD (12) and FIDELIO-DKD (13) studies.